Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Methane is a powerful greenhouse gas, and cows are a major source of it. A group of scientists is developing a proof of ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

The global protein a resins industry is experiencing unprecedented growth, with projections indicating a significant increase ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

About CHIKV VLP CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older.

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

The following is a summary of “Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study,” published in the January 2025 issue ...

as exhibited by inhibition of proliferation of HER-2-expressing cell lines and phosphorylation of the HER-2 protein. The highest dose level of 1.5 mg of each component of the combination vaccine ...